Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628817 | 0.94 | HTR7 (0.33) | HTR7NOS1NOS2CRHR1GPBAR1 | |
| SCHEMBL25015240 | 0.75 | NOS1 (0.40) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL2070847 | 0.75 | NOS1 (0.40) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL2069540 | 0.74 | CRHR1 (0.42) | HTR7CRHR1 | |
| SCHEMBL3623211 | 0.74 | CCR1 (0.42) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL2070175 | 0.72 | LTB4R (0.34) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL2070288 | 0.72 | CRHR1 (0.36) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL31655443 | 0.72 | CCR1 (0.46) | HTR7NOS1NOS2CRHR1ALDH1A1 | |
| SCHEMBL2070002 | 0.72 | IRAK4 (0.44) | HTR7NOS1NOS2CRHR1LMNA | |
| SCHEMBL20436609 | 0.70 | KCNH2 (0.39) | NOS1GPBAR1CYSLTR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | HTR7 89/4885NOS1 1353/4885NOS2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.